Associations between pharmaceutical industry payments to physicians and prescription of PARP inhibitors in the United States

Murayama, Anju; Marshall, Deborah C.

doi:10.1016/j.ygyno.2023.12.011

Cited by 8 publications

(6 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Asosiasi industri makanan dan minuman di negara asal atau negara tujuan ekspor dapat memberikan informasi tentang standar dan persyaratan yang relevan dengan produk kecap (Murayama & Marshall, 2024).…”

Section: Asosiasi Industriunclassified

Strategi Pemasaran Ekspansi Ekspor Produk Kecap Menggunakan Analisis Quantitative Strategic Planning Matrix

Hana Fernanda

2024

Locus

View full text Add to dashboard Cite

Ekspor produk kecap merupakan salah satu aspek penting dalam memperluas pasar internasional bagi perusahaan Indonesia. Arab Saudi, sebagai salah satu pasar potensial, menawarkan peluang yang signifikan untuk produk kecap. Namun, keberhasilan ekspansi ini bergantung pada strategi pemasaran yang tepat. Oleh karena itu, penelitian ini bertujuan untuk mengidentifikasi strategi pemasaran yang efektif untuk ekspansi ekspor produk kecap ke Arab Saudi. Tujuan dari penelitian ini adalah untuk mengetahui strategi pemasaran yang efektif yang dapat digunakan untuk memperluas ekspor produk kecap ke pasar Arab Saudi menggunakan analisis QSPM. Penelitian ini menggunakan metode analisis QSPM (Quantitative Strategic Planning Matrix) untuk mengevaluasi berbagai strategi pemasaran yang mungkin digunakan dalam ekspansi ekspor produk kecap ke Arab Saudi. Data dianalisis dan disusun berdasarkan faktor-faktor eksternal dan internal yang relevan untuk penentuan strategi pemasaran yang optimal. Hasil penelitian ini memberikan wawasan yang berharga bagi perusahaan Indonesia yang berencana untuk memperluas ekspor produk kecap ke pasar internasional, khususnya ke Arab Saudi.

show abstract

Section: Asosiasi Industriunclassified

Strategi Pemasaran Ekspansi Ekspor Produk Kecap Menggunakan Analisis Quantitative Strategic Planning Matrix

Hana Fernanda

2024

Locus

View full text Add to dashboard Cite

show abstract

“…Pharmaceutical companies frequently provide payments to physicians for both research and non-research activities [ 1 , 2 ]. Such financial interactions, while often instrumental in fostering healthcare innovation and improving patient care, also lead to conflicts of interest [ 3 ], potentially biasing physicians’ clinical practice [ 4 – 8 ]. In Japan, pharmaceutical companies have been reported to make substantial non-research payments totaling $1.8 billion, with $1.1 billion allocated for the sponsorship of conferences and lectures geared toward drug promotion, and $236.0 million distributed for lecture and consulting services [ 9 ].…”

Section: Introductionmentioning

confidence: 99%

Cross-sectional analysis of financial relationships between board certified allergists and the pharmaceutical industry in Japan

Murayama,

Senoo

2024

BMC Med Ethics

Self Cite

View full text Add to dashboard Cite

Background Financial interactions between pharmaceutical companies and physicians lead to conflicts of interest. This study examines the extent and trends of non-research payments made by pharmaceutical companies to board-certified allergists in Japan between 2016 and 2020. Methods A retrospective analysis of disclosed payment data from pharmaceutical companies affiliated with the Japanese Pharmaceutical Manufacturers Association was conducted. The study focused on non-research payments for lecturing, consulting, and manuscript drafting made to board-certified allergists from 2016 to 2020. We performed descriptive analyses on payment data. Trends were analyzed using generalized estimating equation models. Results Of the 3,943 board-certified allergists, 2,398 (60.8%) received non-research payments totaling $43.4 million over five years. Lecturing fees comprised 85.7% ($37.2 million) of the total payment amounts. For allergists who received at least one payment, the median amount per allergist was $3,106 (interquartile range: $966 – $12,124), in contrast to a mean of $18,092 (standard deviation: $49,233) over the five-year span. The top 1% and 10% of these allergists accounted for 20.8% and 68.8% of all non-research payments, respectively. The annual payment amounts significantly increased by 7.2% annual increase (95% CI: 4.4 – 10.0%, p < 0.001) each year until 2019, but saw a significant decrease in 2020 amid the COVID-19 pandemic. Conclusion The majority of allergists received non-research payments, with a notable concentration among a small group. Payments increased annually until the pandemic’s onset, which coincided with a substantial decrease. Further research is needed to explore the implications of these financial interactions on clinical practice and patient care in Japan.

show abstract

“…Alongside the introduction of these novel drugs, the global market for breast cancer drugs has been growing substantially, reaching around $26.4 billion in 2022. However, limited head-to-head evidence regarding the safety and effectiveness of these novel drugs [30][31][32][33] has led to fierce competition among manufacturers and increased marketing activities for physicians. [34][35][36] A previous study reported that 78.2% of oncology CPG authors received personal payments for lecturing, consulting and drafting fees from drug companies in Japan in 2016.…”

Section: Introductionmentioning

confidence: 99%

Pharmaceutical company payments to Japanese breast cancer practice guideline authors

Murayama,

Higuchi,

Byreddy

et al. 2024

Clinical and Translational Dis

Self Cite

View full text Add to dashboard Cite

BackgroundThe creation of breast cancer practice guidelines requires proper management of financial relationships with drug companies, as they can introduce conflicts of interest (COIs) among guideline authors. However, little is known about the specific landscape and fraction of financial interactions between the authors of the Japanese Breast Cancer Society Clinical Practice Guidelines for Breast Cancer, edition 2022 (JBCS2022) and drug companies.MethodsUsing payment data publicly disclosed by major drug companies in Japan, this study analysed the personal payments made to the authors of JBCS2022 between 2016 and 2020. We performed descriptive analyses on the payment data.ResultsOf the 149 JBCS2022 authors, 115 (77.2%) received at least one personal payment totaling $3 828 455 from drug companies between 2016 and 2020. The average and median payment amounts per author were $25 772 (standard deviation: $58 197) and $2761 (interquartile range: $322‒$15 828), respectively. The total annual payments per JBCS2022 authors between 2016 and 2019 increased from $588 054 in 2016 to $967 802 in 2019. The JBCS2022 chairperson and vice‐chairperson received $246 936 (fourth highest) and $216 744 (fifth highest) over the 5 years. More than 60% of personal payments to the JBCS2022 authors were not declared by the authors as they were below the declaration threshold set by the Japanese Breast Cancer Society. However, nine authors undeclared personal payments summing $594 615 even though these payments were higher than the thresholds.ConclusionThis study demonstrated that the majority of the breast cancer guideline authors received personal payments from drug companies in Japan. Furthermore, the majority of payments were not declared because of the less transparent COI policy.

show abstract

Associations between pharmaceutical industry payments to physicians and prescription of PARP inhibitors in the United States

Cited by 8 publications

References 43 publications

Strategi Pemasaran Ekspansi Ekspor Produk Kecap Menggunakan Analisis Quantitative Strategic Planning Matrix

Strategi Pemasaran Ekspansi Ekspor Produk Kecap Menggunakan Analisis Quantitative Strategic Planning Matrix

Cross-sectional analysis of financial relationships between board certified allergists and the pharmaceutical industry in Japan

Pharmaceutical company payments to Japanese breast cancer practice guideline authors

Contact Info

Product

Resources

About